ArticleTherapeutic advances in endocrinology and metabolism2026
Iodine concentrations in human milk after maternal high therapeutic potassium iodide dosing during breastfeeding: a contribution from the ConcePTION project.
Article in Therapeutic advances in endocrinology and metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Iodine is an essential element of human milk. However, high therapeutic maternal doses of potassium iodide (KI) during breastfeeding and its effect on the infant have been insufficiently studied. Therefore, human milk samples were collected within the UmbrelLACT study to determine human milk iodine concentration (HMIC) and estimate infant exposure during and after high maternal KI intake. One mother used KI 3 × 50 mg/day as preparation for thyroidectomy at 5 months postpartum. Human milk samples were collected opportunistically during and within 2 weeks after KI discontinuation. Furthermore, milk samples were collected over 24-h periods at 3 weeks post-discontinuation and monthly from 1 month up to 5 months after discontinuation of KI intake. Breastfeeding was temporarily interrupted during maternal treatment, with partial resumption of breastfeeding 1 week after KI discontinuation, complemented with infant formula upon the participant's decision. HMIC were analysed using inductively coupled plasma tandem mass spectrometry (ICP-MS/MS) after basic extraction with tetra-methyl ammonium hydroxide (TMAH) and infant exposure was estimated. Median HMIC were 70.8 (46.6-80.8) µg/mL during and 0.064 (0.016-0.227) µg/mL from day six after maternal treatment stop onwards. After discontinuation of KI intake, HMIC decreased quickly and remained within reference range (0.1-0.2 µg/mL). Using the infant requirement of 15 µg/kg/day, relative infant recommended dose (RID
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.